Bessemer Group Inc. Has $385,000 Holdings in Glaukos Corporation $GKOS

Bessemer Group Inc. lowered its position in Glaukos Corporation (NYSE:GKOS) by 62.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 3,573 shares of the medical instruments supplier’s stock after selling 5,880 shares during the period. Bessemer Group Inc.’s holdings in Glaukos were worth $385,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of GKOS. Janus Henderson Group PLC raised its stake in Glaukos by 183.4% during the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock worth $340,855,000 after buying an additional 1,953,578 shares during the last quarter. Primecap Management Co. CA grew its holdings in Glaukos by 49.8% during the 4th quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after acquiring an additional 1,123,140 shares during the period. Goldman Sachs Group Inc. grew its holdings in Glaukos by 209.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after acquiring an additional 913,458 shares during the period. Millennium Management LLC raised its position in shares of Glaukos by 75.3% in the 4th quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock worth $181,751,000 after acquiring an additional 691,289 shares in the last quarter. Finally, UBS Group AG raised its position in shares of Glaukos by 316.0% in the 4th quarter. UBS Group AG now owns 873,942 shares of the medical instruments supplier’s stock worth $98,677,000 after acquiring an additional 663,849 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on GKOS shares. Citigroup upped their target price on Glaukos from $162.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Piper Sandler reiterated an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a report on Wednesday, July 1st. BTIG Research reissued a “buy” rating and issued a $164.00 price target on shares of Glaukos in a research note on Monday, July 13th. Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Finally, HC Wainwright assumed coverage on shares of Glaukos in a research report on Monday, July 6th. They set a “buy” rating and a $168.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $154.85.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 10,000 shares of Glaukos stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $155.00, for a total value of $1,550,000.00. Following the transaction, the chief financial officer owned 43,681 shares of the company’s stock, valued at $6,770,555. This trade represents a 18.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 61,273 shares of company stock worth $8,882,003. 5.90% of the stock is currently owned by insiders.

Glaukos Stock Up 0.8%

GKOS stock opened at $153.40 on Friday. The stock’s 50 day simple moving average is $135.85 and its 200 day simple moving average is $123.44. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $161.53. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The company has a market cap of $9.01 billion, a P/E ratio of -46.77 and a beta of 0.75.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share. The business’s revenue was up 41.2% on a year-over-year basis. On average, research analysts expect that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.